Time for TED thread on MAM.
I hold so this is probably a blatant ramp, but take a look.
The share is now off its low of 11.5p.
Although many got burnt in thr over hype a few years ago, I think the company
Is now well positioned for advancement.
Management have said that more Nucleopure machine sales are in the pipeline.

Have a listen to TEDs CE here, http://www.wallstreetreporter.com/profiles/TepnelLifeSciences.html

Guardian
Finally, it's worth keeping an eye on Tepnel Life Sciences. Market professionals reckon the AIM-listed DNA technology group has been overlooked in the past month and could now enjoy a good run. They note directors recently bought stock and point out that Tepnel's acquisition of Orchid Diagnostics should significantly boost the company's revenue stream and help it reach a much broader customer base. Tepnel closed 0.5p higher at 13p last night.

Sunday Telegraph
Tepnel is close to completing a second acquisition, having just bought the DNA-testing division of Orchid BioSciences, which allows it to enter the US market and increase the customer base for its DNA technology. Buy at 14.25p, the paper says.
regards
dave

Welcome to this Tepnel Life Sciences thread, As I am a registered blind person I can only list an update each week on the thread as information comes in direct from the company, my stock broker and others in the market place. I welcome any contribution to the thread for the benefit of all

The news from the market place is that Tepnel Life Sciences share price is trading at a discounted price of 8.50p giving an opportunity to make profits on the back of the share price. Market Cap is 20.43 million.

TED is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Target markets are pharmaceutical, biotechnology, healthcare, hospitals, academic/research institutes, food manufacturers and regulatory authorities.

The most recent news from the company is that AXA S.A. now hold 27,732,428 voting right shares (16.27%.) of the issued shares. // the Major Investment of AXA S.A. gives a strong influence to Buy shares with TED the comfort factor. /

Positive news Tepnel preferred supplier agreement with AstraZeneca for DNA extraction services is extended. Share price responds by trading up 0.60p to 14p.

myway-------I don't know where you obtained the sp of TED as being 14p, they were as you say up 0.62p on the day, but the sp is 9.62p. I would like to see them @ 14p and maybe we shall see that over the next 12 months or so.
2517

2517GEORGE So sorry I posted the wrong price...
Positive news Tepnel preferred supplier agreement with AstraZeneca for DNA extraction services is extended. The Share price responded by trading up 0.75p to 6.00p since the announcement. Now I understand why AXA S. A , Holds 27,732,428 shares in the company./

myway----you still can't get it right, they have not been as low as 6p for ages.
2517

2517GORGE Today's price 9.755p.

Update I have had a telephone conversation with my contact at Tepnel Life. He informed me that the company was very pleased with business at the present time, TEDs agreement with AstraZenca interacted a major step in the companys marketing, only to be enhanced by the news that TED has signed a two year global distribution agreement with world's largest online supplier of antibodies, Abcam.

At the end of our telephone conversation I felt that the company is now well in line to take on new clients and extra business for their life sciences products. I look forward to the next announcement from the company, I will now increase my stock holdings in the company. /

one you must have

Been quite strong last couple of days, results not due until Sept, so maybe news around the corner, anyone have any idea's?
2517

I noticed this one too George: Interims to 30 June are due out tomorrow so presumably looking good

Toya, TED posted their last interims 5/9/07 I didn't realise they were due out so soon. Thanks, Good Luck.
2517

Pretty sure I read that on their website - we'll soon know!

Substantial increase in revenues and profits


Manchester, UK, Stamford, USA, 31 July 2008: Tepnel Life Sciences plc (AIM: TED), the international Molecular Diagnostics and Research Products and Services Group, announces interim results for the 6 month period ended 30 June 2008.


'Tepnel continues to deliver very strong revenue and operating profit growth across its entire business. Our new purpose built, state-of-the-art pharmaceutical services facility, along with our recently launched Biopharmaceutical and Genotyping services, have been a great success with strong customer demand.

Additionally, Tepnel's immunological products are showing good growth and have now begun to penetrate worldwide markets. Tepnel's Molecular Diagnostics division also continues to exhibit strong growth led by our LifeMatch range of products and our Elucigene CF and QST*R genetic tests' stated Ben Matzilevich, Tepnel's Chief Executive Officer. 'We believe Tepnel is very well positioned for future growth bolstered by a growing menu of novel molecular diagnostic products and demand for our advanced pharmaceutical outsourcing services. Our strong H1 performance and positive outlook are testament to the loyalty, commitment and dedication of Tepnel's staff and shareholders alike.'


2008 Highlights


*

Revenue increased to 11.8m from 8.8m, an increase of 34% compared to the prior period and 29% on a constant currency basis

*

Gross profit increased 34% to 6.9m compared to 5.1m in 2007

*

An increase of 149% in operating profit to 1.5m from 0.6m in 2007

*

EBITDA increased 118% to 1.9m from 0.9m in 2007

*

Operating cash inflow increased to 1.5m from a cash outflow of 0.2m in 2007

*

Tepnel continues to deliver significant and sustained growth in both revenue and operating profit across both divisions in line with its strategic and operational plans:

Research Products and Services revenue increased by 28% driven by the strong demand for its pharmaceutical outsourcing services from its new state-of-the-art facility in Livingston and newly introduced Biopharmaceutical and Genotyping service lines


Molecular Diagnostics revenue increased by 39% driven by the Transplant Diagnostics business line. The LifeMatch range of products continued to show strong growth compared to the prior period

Back from a couple of weeks in Austria, TED doing very nicely.
2517

isit time to sell

A very steep climb indeed! I wouldn't want to buy just now.

BAYLIS well called, in the short term at least. Longer term I believe the management are going to take TED much further than current sp but, like all shares after a burst upwards some profit taking is desirable.
Toya, rather belatedly, you were correct about the timing of results. Good luck all.
2517

George: I agree with you, Tepnel looks like a promising little pharmaco; not sure that it's pulled back enough to buy for longer term just yet though. 9.5-10p would look reasonable. Chairman, Finance Director, and a third director topped up recently.

Approach for the co.
2517

If TED is taken over then somewhere north of 19p should be achieved, imo.
2517

Good volume (for TED) yesterday and again today.
2517